MicroRNA AND TUBERCULOSIS

In 2015, more than 10% of tuberculosis (TB)-related deaths were attributable to M. tuberculosis with multiple drug-resistance (MDR-TB) and extensively drug-resistance (XDR-TB) (WHO 2016). In combination with insufficient commitment to the treatment regimen, the genetic heterogeneity and clonality of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	V. V. Eremeev, V. V. Evstifeev, G. S. Shepelkova, A. E. Ergeshova, M. A. Bagirov
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2018
Materias:	tuberculosis microrna innate and adaptive immune response biomarkers Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/8f1cabfc42b147ab88f4c0f282339361
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8f1cabfc42b147ab88f4c0f282339361
record_format	dspace
spelling	oai:doaj.org-article:8f1cabfc42b147ab88f4c0f2823393612021-11-22T07:09:49ZMicroRNA AND TUBERCULOSIS2220-76192313-739810.15789/2220-7619-2018-3-309-315https://doaj.org/article/8f1cabfc42b147ab88f4c0f2823393612018-11-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/780https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398In 2015, more than 10% of tuberculosis (TB)-related deaths were attributable to M. tuberculosis with multiple drug-resistance (MDR-TB) and extensively drug-resistance (XDR-TB) (WHO 2016). In combination with insufficient commitment to the treatment regimen, the genetic heterogeneity and clonality of the patient's M. tuberculosis, as well as the poor permeability of the tuberculosis granuloma for the drug, can lead to monotherapy, despite the use of several drugs, which further promotes the spread of MDR and XDR-TB. Of particular concern is the rapid spread of resistance to newly introduced into clinical practice second-line drugs, intended for the treatment of MDR-TB — delamanid and bedaquiline. Thus, the spread of drug resistance to chemotherapy, along with the limited possibilities of chemotherapy in patients with MDR-TB and XDR-TB, dictate the need to supplement canonical chemotherapy with TB treatment methods directed at the host. MicroRNAs (miRs) are short sequences of single-stranded RNA that control up to 60% of genes encoding protein synthesis at a post-transcriptional level. Accumulating data points to the essential role of miRs in fine tuning the host response to infection, primarily by modulating the expression of proteins involved in the reactions of innate and adaptive immune responses. Despite the fact that the established functions of miRs activity are intracellular, a number of studies have discovered highly stable extracellular miRs circulating in blood. Currently, the possibility of using these molecules as biomarkers is being actively investigated. Chronic TB inflammation is characterized by parallel or step-bystep development of regulatory and pro-inflammatory processes that affect the severity and outcome of the disease. Both pro- and anti-inflammatory effects are elements of the bacterial strategy in the struggle for survival in the host organism. In this review we discuss the role of miRs as markers of tuberculosis infection, the nature and prognosis of the course of the disease, the involvement of miRs in the regulation of the innate and adaptive immunity in tuberculosis infection, and the perspectives for clinical usage of miRs as means for diagnosis and treatment of tuberculosis.V. V. EremeevV. V. EvstifeevG. S. ShepelkovaA. E. ErgeshovaM. A. BagirovSankt-Peterburg : NIIÈM imeni Pasteraarticletuberculosismicrornainnate and adaptive immune responsebiomarkersInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 8, Iss 3, Pp 309-315 (2018)
institution	DOAJ
collection	DOAJ
language	RU
topic	tuberculosis microrna innate and adaptive immune response biomarkers Infectious and parasitic diseases RC109-216
spellingShingle	tuberculosis microrna innate and adaptive immune response biomarkers Infectious and parasitic diseases RC109-216 V. V. Eremeev V. V. Evstifeev G. S. Shepelkova A. E. Ergeshova M. A. Bagirov MicroRNA AND TUBERCULOSIS
description	In 2015, more than 10% of tuberculosis (TB)-related deaths were attributable to M. tuberculosis with multiple drug-resistance (MDR-TB) and extensively drug-resistance (XDR-TB) (WHO 2016). In combination with insufficient commitment to the treatment regimen, the genetic heterogeneity and clonality of the patient's M. tuberculosis, as well as the poor permeability of the tuberculosis granuloma for the drug, can lead to monotherapy, despite the use of several drugs, which further promotes the spread of MDR and XDR-TB. Of particular concern is the rapid spread of resistance to newly introduced into clinical practice second-line drugs, intended for the treatment of MDR-TB — delamanid and bedaquiline. Thus, the spread of drug resistance to chemotherapy, along with the limited possibilities of chemotherapy in patients with MDR-TB and XDR-TB, dictate the need to supplement canonical chemotherapy with TB treatment methods directed at the host. MicroRNAs (miRs) are short sequences of single-stranded RNA that control up to 60% of genes encoding protein synthesis at a post-transcriptional level. Accumulating data points to the essential role of miRs in fine tuning the host response to infection, primarily by modulating the expression of proteins involved in the reactions of innate and adaptive immune responses. Despite the fact that the established functions of miRs activity are intracellular, a number of studies have discovered highly stable extracellular miRs circulating in blood. Currently, the possibility of using these molecules as biomarkers is being actively investigated. Chronic TB inflammation is characterized by parallel or step-bystep development of regulatory and pro-inflammatory processes that affect the severity and outcome of the disease. Both pro- and anti-inflammatory effects are elements of the bacterial strategy in the struggle for survival in the host organism. In this review we discuss the role of miRs as markers of tuberculosis infection, the nature and prognosis of the course of the disease, the involvement of miRs in the regulation of the innate and adaptive immunity in tuberculosis infection, and the perspectives for clinical usage of miRs as means for diagnosis and treatment of tuberculosis.
format	article
author	V. V. Eremeev V. V. Evstifeev G. S. Shepelkova A. E. Ergeshova M. A. Bagirov
author_facet	V. V. Eremeev V. V. Evstifeev G. S. Shepelkova A. E. Ergeshova M. A. Bagirov
author_sort	V. V. Eremeev
title	MicroRNA AND TUBERCULOSIS
title_short	MicroRNA AND TUBERCULOSIS
title_full	MicroRNA AND TUBERCULOSIS
title_fullStr	MicroRNA AND TUBERCULOSIS
title_full_unstemmed	MicroRNA AND TUBERCULOSIS
title_sort	microrna and tuberculosis
publisher	Sankt-Peterburg : NIIÈM imeni Pastera
publishDate	2018
url	https://doaj.org/article/8f1cabfc42b147ab88f4c0f282339361
work_keys_str_mv	AT vveremeev micrornaandtuberculosis AT vvevstifeev micrornaandtuberculosis AT gsshepelkova micrornaandtuberculosis AT aeergeshova micrornaandtuberculosis AT mabagirov micrornaandtuberculosis
_version_	1718417990480822272

MicroRNA AND TUBERCULOSIS

Ejemplares similares